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Abstract: Starting in 2006, vaccination against human papillomavirus (HPV) has been 
progressively implemented in most developed countries. Two vaccines have been successfully 
used, a bivalent vaccine targeting HPV-related cancers (bHPV) and a quadrivalent vaccine (qHPV) 
targeting both HPV-related cancers and genital warts. Between December 2014 and June 2015, 
a new nonavalent HPV vaccine (9vHPV) was granted marketing authorization in the USA and 
Europe. The 9vHPV was developed from the qHPV and includes five additional HPV types that 
should increase the level of protection toward HPV-related cancers. Efficacy and/or immunoge-
nicity of 9vHPV has been assessed in eight clinical studies. The 9vHPV vaccine induced a very 
robust immune response against all vaccine types, with seroconversion rates close to 100%. The 
safety profile of 9vHPV is comparable to that of qHPV. Local reactions, especially swelling, 
have been more frequently reported after 9vHPV than qHPV, and this slightly increases when 
the 9vHPV is coadministered with other vaccines. The additional coverage offered by the 9vHPV 
may prevent a significant proportion of HPV-related cancers (variable between 8% and 18%) 
depending on the local distribution of high-risk HPV types in the population. It is impossible, 
at present, to anticipate the actual impact of the wide use of the 9vHPV in comparison with 
the bHPV or the qHPV, since it depends on many variables including duration of protection, 
potential cross-protection toward nonvaccine types, and herd immunity effect.
Keywords: human papillomavirus vaccine, immunogenicity, vaccine safety, cervical cancer, 
head and neck cancer, genital warts
Background
In 1842, the Italian physician Rigoni-Stern,1 in Verona, observed that deaths after 
cervical cancer seldom occurred in virgins and nuns, being more frequent in married 
women, widows, and prostitutes. This was the first observation suggesting a link 
between sexual contact and cervical cancer. But it was only in the early 1970s that 
scientific experiments tried to establish a causal relationship between human papil-
lomavirus (HPV) infection and cervical cancer. zur Hausen2,3 received the Nobel 
Prize in Medicine in 2008 for his studies on the oncogenic role of HPVs. Based on 
epidemiological observation, Muñoz et al4 in 2003 listed 15 HPV types (16, 18, 31, 
33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82) as high-risk types with a clear car-
cinogenic role, forming the basis for an epidemiological classification of HPV types 
associated with cancer. To date, the World Health Organization’s International Agency 
for Research on Cancer (IARC) has classified twelve HPV types (16, 18, 31, 33, 35, 
39, 45, 51, 52, 56, 58, and 59) among the “Group 1 carcinogens”.5
As a result of the continuous progress in this field, two vaccines against HPV 
infection have been developed. A quadrivalent vaccine (qHPV) gained approval from 
the US Food and Drug Administration (FDA) in 2006 and also received a positive 
opinion from the European Medicine Agency. A bivalent vaccine (bHPV) received 
a positive opinion from the European Medicine Agency in 2007 and was approved 
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by the FDA in 2009. Both qHPV and bHPV include HPV 
types 16 and 18, which represent the most common cause 
of cervical cancer. In addition, qHPV includes HPV types 
6 and 11, which are responsible for the majority of genital 
warts. The characteristics of the two vaccines are summa-
rized in Table 1.
To date, most of the industrialized countries have intro-
duced HPV vaccination.6,7 In addition, GAVI started the first 
HPV vaccine demonstration program in Kenya in 2013, thus 
vaccinating 300,000 girls and helping seven countries initi-
ate other demonstration programs.8 Implementation of HPV 
vaccination programs varies a lot across the countries. Most 
of the industrialized countries recommend HPV vaccination 
for at least one cohort of adolescent or preadolescent girls 
(starting from 9 years of age). Catch-up programs, extended 
to older girls and women, have been implemented in nine 
European countries,9 USA,10 and Canada.11 More recently, 
few countries, including the USA, extended the HPV vaccine 
recommendation to the male population as well.
In December 2014, a nonavalent vaccine (9vHPV), devel-
oped starting from the qHPV, was licensed by the FDA.12 The 
9vHPV gained marketing authorization from the European 
Commission, valid throughout the European Union, in June 
2015.13 The 9vHPV contains type 31, 33, 45, 52, and 58 
antigens in addition to those included in the qHPV. The 
content of 9vHPV is shown in Table 1. The additional high-
risk types included in the 9vHPV should provide a higher 
protection against HPV-related cancers, thus improving the 
overall impact of the vaccination programs. This paper aims 
at reviewing the available evidence on safety, immunogenic-
ity, and potential impact of the 9vHPV.
Efficacy and immunogenicity of the 
9vHPV
Efficacy and/or immunogenicity of the 9vHPV was assessed 
in eight clinical studies, which are summarized in Table 2.
Comparison of 9vHPV against placebo was not acceptable 
since HPV vaccination is recommended and implemented 
in many countries with either bHPV or qHPV. Therefore, 
the strategy used in the clinical development of 9vHPV has 
been based on the following steps:
Step 1:  efficacy of 9vHPV against persistent infection and 
disease related to HPV types 6, 11, 16, or 18 to be 
inferred from noninferior immunogenicity studies 
between 9vHPV and qHPV in girls aged 9–15 years 
and in women and men aged 16–26 years;
Step 2:  efficacy against persistent infection and disease 
related to the new types included in the 9vHPV 
Table 1 Summary characteristics of the licensed vaccines against HPv infection
Vaccine – product name HPV types Vaccine composition
bHPv – Cervarix® 16-18 Type 16 L1 protein 20 µg
Type 18 L1 protein 20 µg
Adjuvanted by AS04, containing:
– MPLa 50 µg
– Adsorbed on Al(OH)3 0.5 mg
qHPv – Gardasil®/Silgard® 6-11-16-18 Type 6 L1 protein 20 µg
Type 11 L1 protein 40 µg
Type 16 L1 protein 40 µg
Type 18 L1 protein 20 µg
Adsorbed on amorphous aluminum 
hydroxyphosphate sulfate adjuvant (225 µg)
9vHPv – Gardasil-9® 6-11-16-18-31-33-45-52-58 Type 6 L1 protein 30 µg
Type 11 L1 protein 40 µg
Type 16 L1 protein 60 µg
Type 18 L1 protein 40 µg
Type 31 L1 protein 20 µg
Type 33 L1 protein 20 µg
Type 45 L1 protein 20 µg
Type 52 L1 protein 20 µg
Type 58 L1 protein 20 µg
Adsorbed on amorphous aluminum 
hydroxyphosphate sulfate adjuvant (500 µg)
Note: a3-O-desacyl-4′-monophosphoryl lipid A.
Abbreviation: HPv, human papillomavirus.
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(31, 33, 45, 52, and 58) to be demonstrated in girls 
and women aged 16–26 years;
Step 3:  demonstration of noninferior immunogenicity against 
the 9vHPV types in boys and girls aged 9–15 years 
and men aged 16–26 years, compared to women 
aged 16–26 years (Figure 1).
No direct comparison between 9vHPV and bHPV can 
be performed in terms of efficacy due to the fact that cross-
protection of bHPV toward HPV types not included in the 
vaccine is widely under debate.
Efficacy of 9vHPV against persistent 
infection and disease related to types 6, 
11, 16, and 18
Efficacy against types 6, 11, 16, and 18 was anticipated 
to be similar between 9vHPV and qHPV. For this reason, 
Table 2 Summary of the clinical studies to evaluate immunogenicity, efficacy, and safety of 9vHPV, in relation to the strategy used for 
the clinical developmenta
Study 
code
Objectives Strategic 
objective
Population References
001 Noninferior immunogenicity against HPv types 6, 11, 16, 
and 18 and efficacy against HPV types 31, 33, 45, 52, and 
58 of 9vHPv compared to qHPv in women 16 through 
26 years of age
Steps 1 and 2 N=14,204: 7,099 receiving 
9vHPv and 7,105 receiving 
qHPv vaccine
Joura et al14
002 immunogenicity of 9vHPv in girls and boys 9 through 
15 years of age and women 16 through 26 years of age
Step 3 N=3,066: 1,932 girls; 666 
boys; and 468 women 
receiving 9vHPv
van Damme et al18
003 immunogenicity of 9vHPv in men 16 through 26 years of 
age and women 16 through 26 years of age
Step 3 N=2,515: 1,103 HM; 313 
MSM; and 1,099 women 
receiving 9vHPv
Castellsagué et al19
006 Administration of 9vHPv to girls and women 12 through 
26 years of age previously vaccinated with qHPv vaccine
9vHPv 
revaccination 
after qHPv
N=921: 615 receiving 9vHPv 
and 306 receiving placebo
Garland et al20
005 and 
007
Concomitant administration of 9vHPv with vaccines 
recommended routinely in girls and boys 11 through  
15 years of age
9vHPv 
coadministration
N=2,295: 1,147 boys and girls 
in the concomitant group and 
1,148 in the nonconcomitant 
group
Schilling et al;21 
Kosalaraksa et al22
009 immunogenicity of 9vHPv in girls 9 through  
15 years of age
Step 1 N=600: 300 receiving 9vHPv 
and 300 receiving qHPv 
vaccine
vesikari et al15
010 immunogenicity of two doses of 9vHPv in girls and boys 
9 through 14 years of age and three doses of 9vHPv in 
girls 9 through 14 years of age and women 16 through 
26 years of age
Two doses 
schedule 
evaluation
N=1,518: 753 girls; 451 boys; 
and 314 women
european 
Medicines Agency17
020 evaluated immunogenicity of 9vHPv in men 16 through 
26 years of age
Step 1 N=500: 249 receiving 9vHPv 
and 251 receiving qHPv 
vaccine
van Damme et al16
Notes: aStep 1: the efficacy of 9vHPV against persistent infection and disease related to HPV types 6, 11, 16, or 18 to be inferred from noninferior immunogenicity studies 
between 9vHPV and the qHPV vaccine in girls 9–15 years, women and men 16–26 years; Step 2: the efficacy against persistent infection and disease related to the new types 
included in the 9vHPv (31, 33, 45, 52, and 58) to be demonstrated in girls and women 16–26 years; Step 3: the demonstration of noninferior immunogenicity against the 
9vHPv types in boys and girls 9–15 years and men 16–26 years, compared to women 16–26 years.
Abbreviations: HPv, human papillomavirus; HM, heterosexual men; MSM, men who have sex with men.
Figure 1 Strategy followed to assess immunogenicity and efficacy of 9vHPV in 
premarketing clinical studies.
Abbreviation: HPv, human papillomavirus. 
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it was primarily assessed using a bridging strategy that 
demonstrated noninferior immunogenicity of 9vHPV 
compared with qHPV in women aged 16–26 years (Study 
001),14 girls aged 9–15 years (Study 009),15 and men aged 
16–26 years (Study 020).16 Geometric mean titers (GMTs) for 
anti-HPV 6, 11, 16, and 18 are summarized on a logarithmic 
scale in Figure 2. No significant difference in GMT has been 
demonstrated in any age group between 9vHPV and qHPV 
recipients. Seroconversion rates within 1 month after dose 3 
in the 9vHPV populations were between 99.8% and 100%.
Efficacy of 9vHPV against persistent 
infection and disease related to types 31, 
33, 45, 52, and 58
Study protocol 001 has been used to assess the efficacy of 
9vHPV against persistent infection and disease due to the 
new types included in the nonavalent vaccine in women aged 
16–26 years.14,17 A total of 14,204 women (9vHPV =7,099; 
qHPV =7,105) were followed up for 67 months after admin-
istration of dose 3, with a median duration of 43 months after 
dose 3, in a randomized, double-blind clinical trial.
The per-protocol efficacy (PPE) population included all 
women who were seronegative on day 1 of the study and 
had negative results on polymerase chain reaction assays 
for the relevant HPV type from day 1 through month 7. 
High-grade cervical intraepithelial neoplasia, adenocarci-
noma in situ, invasive cervical carcinoma, high-grade vulvar 
intraepithelial neoplasia, high-grade vaginal intraepithelial 
neoplasia, vulvar cancer, and vaginal cancer were the con-
ditions representing the study end points. The efficacy of 
9vHPV on both persistent infection and disease related to 
the HPV types 31, 33, 45, 52, or 58 is summarized in Table 3. 
In the PPE population, the risk reduction for both persistent 
infection and low-/high-grade disease has been very high, 
being close to 100% for most of the considered end points. 
Only one case of high-grade disease (CIN 2) occurred in the 
9vHPV PPE population, and this was related to HPV type 58 
infection. Remarkably, this subject also had positive results 
for HPV type 56 both at baseline and later on until the time 
of diagnosis, thus suggesting that coinfection by a HPV type 
not covered by the 9HPV was a plausible cause of vaccine 
failure. The incidence of both persistent infection and low-/
high-grade disease related to HPV types 6, 11, 16, and 18 was 
similar in the 9vHPV and qHPV groups, and no significant 
risk reduction was detected.
The modified intention-to-treat (ITT) population included 
women who received at least one dose of vaccine and for 
whom there was at least one measurement of efficacy for 
the corresponding end point. The ITT population included 
both naïve and non-naïve women. The 9vHPV vaccine 
efficacy toward high-grade disease in the subgroup of non-
HPV-infected women was 42.5% (95% confidence interval: 
7.9–65.9). Disease rates in the subgroup of HPV-infected 
women were similar in both 9vHPV and qHPV groups.
Noninferior immunogenicity against 
the 9vHPv types in boys and girls aged 
9–15 years and men aged 16–26 years, 
compared to women aged 16–26 years
The immune response to 9vHPV with regard to the new 
HPV types has been assessed in the younger age groups 
and in men aged 16–26 years in comparison with women 

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Figure 2 Comparison of immune responses (GMT) between 9vHPv and qHPv vaccine for HPv types 6, 11, 16, and 18 in 9–15 year old girls and 16–26 year old women 
and men.
Abbreviations: GMT, geometric mean titer; HPv, human papillomavirus.
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aged 16–26 years.18,19 Seroconversion rates measured at 
month 7 were close to 100% in all age groups.17 Immuno-
genicity levels in terms of GMT at month 7 are shown in 
Figure 3. The immune response to the new antigen types 
included in the 9vHPV is comparable between the sexes 
and is slightly higher in the younger age groups in com-
parison to women and men aged 16–26 years. On the basis 
of such bridging immunogenicity evaluation, the efficacy 
of 9vHPV against the new vaccine types is inferred from 
women aged 16–26 years to men aged 16–26 years and 
younger age groups.17
In conclusion, the 9vHPV induced a very robust immune 
response against all vaccine types, with seroconversion 
rates close to 100%. GMTs were higher in the younger age 
groups (boys and girls) than in the men and women aged 
16–26 years.
Use of 9vHPv in individuals previously 
vaccinated with qHPv
Immunogenicity of 9vHPV in females aged 12–26 years 
who were previously vaccinated with three doses of qHPV 
has been assessed in a double-blind, placebo-controlled 
randomized trial (Study 006).20 Between 98.3% and 100% 
of the study population previously vaccinated with qHPV 
seroconverted to the new types included in the 9vHPV. The 
level of immune response elicited by 9vHPV in previously 
Table 3 Efficacy of 9vHPV on persistent HPV infection and on cervical, vulvar, and vaginal disease (HPV types 31, 33, 45, 52, or 58) 
in the per-protocol efficacy population14
Outcome 9vHPV (N=7,099) qHPV (N=7,105) Risk reduction
Cases Cases/1,000 
person-years
Cases Cases/1,000 
person-years
95% CI
Persistent infection
$6 months 35 2.1 810 52.4 96.0 (94.4–97.2)
$12 months 21 1.3 544 34.5 96.3 (94.4–97.7)
Cervical, vulvar, and vaginal
CiN1, condyloma, viN1, and vaiN1 2 0.1 82 4.3 97.6 (91.7–99.6)
CiN2/3, viN2/3, vaiN2/3, or worse 1 0.1 30 1.6 96.7 (80.9–99.8)
Cervical disease
CiN1 1 0.1 69 4.0 98.6 (92.4–99.9)
CiN2/3 or worse 1 0.1 27 1.5 96.3 (79.5–99.8)
vulvar and vaginal disease
Condyloma 0 0.0 3 0.2 100 (−71.6 to 100)
viN1 or vaiN1 1 0.1 12 0.6 91.7 (51.3–99.6)
viN2/3, vaiN2/3, or worse 0 0.0 3 0.2 100 (−71.5 to 100)
Note: Adapted with permission from Joura e, Giuliano AR, iversen O-e, et al. A 9-valent HPv vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 
2015;372(8):711–723.14
Abbreviation: CI, confidence interval.
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Figure 3 Comparison of immune responses (GMT) at month 7 after 9vHPv vaccination to HPv types 31, 33, 45, 52, and 58 in 9–15 year old girls and boys, and 16–26 year 
old women and men.
Abbreviations: GMT, geometric mean titer; HPv, human papillomavirus; M, male; F, female.
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vaccinated individuals was compared to that measured in the 
pivotal Study 001 in a naïve female population.14 The immune 
response to HPV types 6, 11, 16, and 18 after vaccination with 
9vHPV was higher in women aged 16–26 years who were 
previously vaccinated with qHPV than in those receiving 
9vHPV only. On the contrary, the immune response to HPV 
types 31, 33, 45, 52, and 58 was lower in those previously 
vaccinated with qHPV (Figure 4). In any case, such an obser-
vation is difficult to interpret since there is no established 
threshold for protection in terms of antibody titers.
Use of 9vHPv with a two-dose schedule
Immunogenicity of 9vHPV has been assessed in girls and 
boys aged 9–14 years receiving a two-dose schedule (either 
6- or 12-months interval) in comparison to girls aged 
9–14 years and women aged 16–26 years receiving three 
doses at 0, 2, and 6 months.17 One month following the last 
dose of the assigned regimen, seroconversion rates across all 
groups were between 97.9% and 100%. GMTs for each of the 
nine vaccine HPV types were higher in girls and boys who 
received two doses of 9vHPV (at either 0–6 or 0–12 months) 
than women aged 16–26 years who received three doses (at 
0, 2, and 6 months). On the basis of this immunogenicity 
bridging, the efficacy of a two-dose regimen of 9vHPV in 
girls and boys aged 9–14 years was inferred.
In the same study, in girls and boys aged 9–14 years, 
GMTs at 1 month after the last vaccine dose were numerically 
lower for some vaccine types after a two-dose schedule than 
after a three-dose schedule (ie, HPV types 18, 31, 45, and 52 
after 0 and 6 months and HPV type 45 after 0 and 12 months). 
The clinical relevance of these findings is unknown.
Concomitant administration of 9vHPv 
with other vaccines usually given to 
adolescents
The 9vHPV has been coadministered with Neisseria 
meningitidis serotypes A/C/Y/W-135 or diphtheria/tetanus/
acellular pertussis (Tdap) vaccines in a population of boys 
and girls aged 9–14 years21 and with diphtheria/tetanus/
acellular pertussis/inactivated poliomyelitis vaccine (Tdap-
IPV) in a population of boys and girls aged 11–14 years.22 
In both studies, the immune response to all component of 
administered vaccines was noninferior when compared with 
nonconcomitant administration.
Safety of the 9vHPV
Safety of the 9vHPV has been assessed during the clinical 
development in a large population of about 16,000 
individuals.17 The most common adverse events reported 
among recipients who received the vaccines were injection-
site adverse reactions and headache, which were mild to 
moderate in intensity (Table 4). Swelling at the injection 
site has been more frequently reported among recipients 





+39 +39 +39 +39 +39 +39 +39 +39 +39
3UHYT+39 1RT+39
*0
7
Figure 4 Comparison of immune responses (GMT) at month 7 after 9vHPv vaccination in 16–26 year old women that received or not previous vaccination with qHPv.
Abbreviation: GMT, geometric mean titer.
Table 4 Summary of the safety profile of 9vHPV
Adverse reaction Frequencya
Pain, swelling, and redness at the  
injection site
very common
Headache very common
Dizziness Common
Nausea Common
Notes: Adverse reactions reported with a frequency of at least 0.1% during clinical 
trials.17 avery common: $1/10; common: $1/100 to ,1/10.
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of the 9vHPV vaccine than recipients of the qHPV both in 
women aged 16–26 years (40.0% vs 28.8%)14 and girls aged 
9–15 years (47.8% vs 36.0%).15
Headache has been the most frequent systemic adverse 
event related to vaccine administration, followed by pyrexia, 
nausea, dizziness, and fatigue. The overall frequency of 
vaccine-related systemic adverse events was similar in 
9vHPV and qHPV vaccines (Figure 5).
Three serious adverse events were reported that were 
considered by the investigators as being related to the vac-
cination: one case of asthma in a 10-year-old boy, who was 
hospitalized and then fully recovered;18 one case of a 21-year-
old woman who was hospitalized for severe headache and 
fever, discharged after 2 days with a possible diagnosis of 
viral infection, and fully recovered after 8 days;18 and one 
case of an 18-year-old woman who experienced purulent 
tonsillitis 2 days after receiving dose 1 of 9vHPV vaccine, 
was hospitalized, and then fully recovered.20
No report on postmarketing safety data is available to 
date. In 2014, Centers for Disease Control and Prevention 
published a report analyzing the events reported to the 
Vaccine Adverse Event Reporting System (VAERS) follow-
ing qHPV vaccination from June 2006 through March 2014.23 
In that report, about 92% of the qHPV reports were classified 
as nonserious. The most commonly reported adverse events 
were syncope (fainting), dizziness, nausea, headache, fever, 
and injection-site reactions (pain, swelling, and redness). 
From a preliminary analysis of the VAERS database, in 2015, 
excluding reports related to programmatic errors (incorrect 
product storage, inappropriate schedule, etc), 386 reports of 
adverse events after 9vHPV have been submitted to VAERS, 
in comparison to 1,581 reports related to qHPV (personal 
observation). The most frequent events reported after 9vHPV 
vaccination in 2015 were dizziness, syncope, headache, and 
injection-site reactions.
In conclusion, the safety profile of 9vHPV is compa-
rable to qHPV, but local reactions, especially swelling, 
have been more frequently reported after 9vHPV than after 
qHPV administration. Concomitant administration with 
other vaccines has been shown to slightly increase the local 
reactogenicity. Headache and fever have been the most fre-
quent systemic adverse events reported after 9vHPV, with a 
frequency comparable to qHPV vaccination.17
Anticipated impact of the 9vHPV
The anticipated impact of 9vHPV in comparison with bHPV 
and qHPV is related to its larger coverage of high-risk HPV 
types. Since cross-protection against HPV types not included 
in the vaccine has not been demonstrated, the potential impact 
of 9vHPV use is strictly associated with the prevalence of 
disease related to the additional five types covered by the new 
vaccine. Worldwide, the distribution of HPV types among 
HPV-related cancers significantly varies. A large review 
done by Zhai and Tumban24 showed that protection given 
by 9vHPV would cover HPV types associated with 92% of 
cervical cancers in North America, 90.9% in Europe, 86.5% 
in Australia, and 89.9% worldwide. Therefore, the additional 
coverage provided by the new vaccine against cervical dis-
ease would be around 13% in North America and Europe, 
8.8% in Australia, and 18.4% worldwide (Figure 6).
The Centers for Disease Control and Prevention’s analy-
sis on high-quality data from the National Program of Cancer 
Registries and the National Cancer Institute’s Surveillance, 
Epidemiology, and End Results program, over the period 
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Figure 5 Frequency of vaccine-related systemic adverse events (systemic adverse events included fever, headache, fatigue, nausea, dizziness, oropharyngeal or abdominal 
pain, myalgia, diarrhea) after 9vHPv and qHPv vaccination (reference citation number).
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2008–2012, showed that of the 38,793 cancers that occurred 
each year in the USA at relevant anatomic sites, approxi-
mately 30,700 could be attributed to HPV. Of these, 24,600 
cancers were attributable to HPV types 16 and 18, and 
28,500 were attributable to 9vHPV types. In particular, 
on average, the additional attributable fraction covered by 
9vHPV accounted for 14.7% of cervical cancer, 18.3% of 
vaginal cancer, 14.2% of vulvar cancer, 9.0% of penile 
cancer, 8.2% of both anal and rectal cancers, and 5.7% of 
oropharyngeal cancers.25
Moreover, projected reduction of CIN 2/3 and low-grade 
intraepithelial lesions due to the broader coverage of 9HPV 
may lead to a stronger impact on screening programs.26
Conclusion
The 9vHPV was licensed by the FDA in December 2014 and 
by the European Commission in June 2015.
Efficacy and/or immunogenicity of 9vHPV has been 
assessed in eight clinical studies. The 9vHPV vaccine induced 
a very robust immune response against all vaccine types, with 
seroconversion rates close to 100%. No significant interfer-
ence was demonstrated when the vaccine was coadministered 
with other vaccines used for adolescent immunization. The 
use of 9vHPV in a group of women previously vaccinated 
with qHPV showed good immunogenicity, even though the 
response to the new types included in the 9vHPV vaccine 
was higher in women not previously vaccinated with qHPV. 
In conclusion, the expected efficacy of 9vHPV is comparable 
to that observed so far with qHPV, but extended to the HPV 
types 31, 33, 45, 52, and 58.
This is the third vaccine available on the global market 
for prevention of persistent infection and disease caused by 
HPV, after a bivalent and a quadrivalent vaccine. Built on the 
clinical experience accumulated with the qHPV, the antici-
pated impact of 9vHPV is linked to the broader coverage 
against five additional types of high-risk HPV, since cross-
protection toward HPV types not included in the vaccine is 
not warranted. Due to the strong differences between the 
bivalent and the nonavalent vaccine, no direct comparison is 
possible at present. In fact, the expected impact of the bHPV 
might be linked to some cross-protection toward HPV types 
not included in the vaccine. Such cross-protection has been 
demonstrated in the early postmarketing phase, but the long-
term impact of cross-protection is at present debatable.27,28
Large clinical studies have demonstrated that 9vHPV 
and qHPV are comparable in terms of immunogenicity and 
efficacy against persistent infection and cervical invasive 
disease. Efficacy against vulvar and vaginal disease due to the 
new types included in the 9vHPV has also been demonstrated, 
even though wide confidence intervals suggest continuous 
evaluation to increase the number of observations and con-
sequently the power of the study. Switching from qHPV to 
9vHPV in the national programs may warrant a significantly 
higher impact on HPV-related cancers both in females and 
males. It is hard to precisely assess the expected impact of the 
additional coverage provided by the five new vaccine types in 
the long run, since the prevalence of HPV types may change 
in the population, which is also under the pressure of HPV 
vaccination programs.29 Moreover, no strong evidence has 
been collected so far on the size of the herd immunity effect 
produced by the different vaccination strategies and by the 
use of different vaccine products. The immune response to 
the new vaccine types included in the 9vHPV is optimal in 
naïve population. Previous vaccination with qHPV seems 
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Figure 6 estimated percentage of cervical cancers attributable to HPv types included in the qHPv and 9vHPv, in North America, europe, Australia, and worldwide.
Note: Data from Zhai and Tumban.24
Abbreviation: HPv, human papillomavirus.
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to also reduce the immune response to subsequent 9vHPV 
vaccination with regard to the five additional types. Since 
there is no certain correlate of protection with antibody levels, 
the clinical significance of such an observation is unclear. 
However, revaccination of individuals already immunized 
with either bHPV or qHPV – with the scope of providing 
protection against the additional five types – should not be 
considered a good policy option.9
The safety profile of 9vHPV is very good and is com-
parable to qHPV. Swelling and pain at the site of injection 
can be higher after 9vHPV vaccination, especially when 
coadministered with other adolescent vaccinations. Such 
evidence should be taken into consideration during mass 
campaigns, since higher local reactogenicity might reduce 
compliance and increase the risk of psychogenic reactions 
to vaccination.30,31
In conclusion, the availability of a new vaccine product 
represents an additional opportunity for implementing effec-
tive HPV vaccination programs. The duration of protection 
of HPV vaccines, potential cross-protection toward non-
vaccine types, and interference between different vaccine 
products are still under debate in the scientific community. 
Continuous surveillance and ad hoc studies to better know 
the circulation of HPV types in the population are paramount 
for monitoring the effectiveness and the overall impact of the 
different vaccine products. The choice of the right vaccine 
product should be guided by local considerations including 
the main target of the program (cervical cancer, other HPV-
related cancers, warty disease), epidemiological situation, 
and pharmacoeconomic assessment.
Disclosure
The author reports no conflicts of interest in this work.
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